Roivant Sciences (ROIV) Current Assets (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Current Assets came in at $5.2 billion in Q1 2026, up 3.35% YoY from $5.0 billion in Q1 2025, and up 1019.79% on a QoQ basis from $461.5 million in Q4 2025.
Roivant Sciences (ROIV) Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Current Assets data on file, last reported at $5.2 billion in Q1 2026.
- Quarterly Current Assets rose 3.35% year-over-year to $5.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 billion (up 3.35% YoY) and the FY2026 annual result came in at $5.2 billion, up 3.35% from the prior year.
- Current Assets rose to $5.2 billion in Q1 2026, from $461.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $6.7 billion in Q1 2024 to a low of $461.5 million in Q4 2025.
- A 5-year average of $3.1 billion and a median of $2.0 billion in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 61.39% — and 2024, when it soared 284.43%.
- Tracing ROIV's Current Assets over 5 years: stood at $1.6 billion in 2022, then slumped by 61.39% to $635.7 million in 2023, then increased by 3.33% to $656.8 million in 2024, then fell by 29.74% to $461.5 million in 2025, then soared by 1019.79% to $5.2 billion in 2026.
- The last three Current Assets figures came in at $5.2 billion (Q1 2026), $461.5 million (Q4 2025), and $4.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.74 Bn |
| Mar 31, 2026 | 5.17 Bn |
| Dec 31, 2025 | 461.46 Mn |
| Sep 30, 2025 | 4.51 Bn |
| Jun 30, 2025 | 4.62 Bn |
| Mar 31, 2025 | 5.00 Bn |
| Dec 31, 2024 | 656.80 Mn |
| Sep 30, 2024 | 5.80 Bn |
| Jun 30, 2024 | 6.00 Bn |
| Mar 31, 2024 | 6.73 Bn |
| Dec 31, 2023 | 635.65 Mn |
| Sep 30, 2023 | 1.55 Bn |
| Jun 30, 2023 | 1.56 Bn |
| Mar 31, 2023 | 1.80 Bn |
| Dec 31, 2022 | 1.65 Bn |
| Sep 30, 2022 | 1.71 Bn |
| Jun 30, 2022 | 2.04 Bn |
| Mar 31, 2022 | 2.15 Bn |
| Dec 31, 2021 | 2.29 Bn |
| Sep 30, 2021 | 2.56 Bn |